US09061G1013 - Common Stock - After market: 112.2 0 (0%)
NASDAQ:BMRN (2/3/2023, 3:30:02 PM)-0.64 (-0.57%)
|GICS Sector||Health Care|
|Earnings (Last)||10-26 2022-10-26/amc||Earnings (Next)||02-21 2023-02-21|
|Ins Owners||0.55%||Inst Owners||98.33%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find more growth stocks the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in Novato, California and currently employs 3,045 full-time employees. The firm's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.
BIOMARIN PHARMACEUTICAL INC
105 Digital Dr
Novato CALIFORNIA 94901
CEO: Jean-Jacques Bienaime
These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors.
A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?
Some stocks are hitting new highs.
BioMarin Pharmaceutical Inc.’s gene therapy Roctavian reduced the annualized rate of bleeding in patients with hemophilia A by 80% in a three-year study.
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
Here you can normally see the latest stock twits on BMRN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.